BRPI0921651A2 - Método para produzir adenovírus recombinante, e partículas virais, e, biorreator - Google Patents

Método para produzir adenovírus recombinante, e partículas virais, e, biorreator

Info

Publication number
BRPI0921651A2
BRPI0921651A2 BRPI0921651-0A BRPI0921651A BRPI0921651A2 BR PI0921651 A2 BRPI0921651 A2 BR PI0921651A2 BR PI0921651 A BRPI0921651 A BR PI0921651A BR PI0921651 A2 BRPI0921651 A2 BR PI0921651A2
Authority
BR
Brazil
Prior art keywords
bioreactor
viral particles
recombinant adenovirus
producing recombinant
producing
Prior art date
Application number
BRPI0921651-0A
Other languages
English (en)
Inventor
Alfred Luitjens
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of BRPI0921651A2 publication Critical patent/BRPI0921651A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00Tissue, human, animal or plant cell, or virus culture apparatus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
BRPI0921651-0A 2008-11-03 2009-10-29 Método para produzir adenovírus recombinante, e partículas virais, e, biorreator BRPI0921651A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19812208P 2008-11-03 2008-11-03
EP08168181 2008-11-03
PCT/EP2009/064265 WO2010060719A1 (en) 2008-11-03 2009-10-29 Method for the production of adenoviral vectors

Publications (1)

Publication Number Publication Date
BRPI0921651A2 true BRPI0921651A2 (pt) 2015-08-18

Family

ID=40344776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921651-0A BRPI0921651A2 (pt) 2008-11-03 2009-10-29 Método para produzir adenovírus recombinante, e partículas virais, e, biorreator

Country Status (16)

Country Link
US (1) US10041049B2 (pt)
EP (1) EP2350268B1 (pt)
JP (1) JP5770633B2 (pt)
KR (1) KR101504392B1 (pt)
CN (1) CN102203242B (pt)
AU (1) AU2009319254B2 (pt)
BR (1) BRPI0921651A2 (pt)
CA (1) CA2742474C (pt)
DK (1) DK2350268T3 (pt)
EA (1) EA019928B1 (pt)
ES (1) ES2532015T3 (pt)
HK (1) HK1160664A1 (pt)
MX (1) MX2011004292A (pt)
NZ (1) NZ593235A (pt)
PL (1) PL2350268T3 (pt)
WO (1) WO2010060719A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5770633B2 (ja) 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
AU2010305768B2 (en) * 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
BR112012008516B1 (pt) * 2009-10-15 2021-10-19 Janssen Vaccines & Prevention B.V. Método para purificar partículas de adenovírus a partir de uma suspensão de célula
AU2011214262B2 (en) * 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
ES2529429T3 (es) 2011-02-10 2015-02-20 Crucell Holland B.V. Sistema de separación de células de membrana de presión neumática alterna
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
JP6851827B2 (ja) * 2013-08-30 2021-03-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞培養中でのウイルスの大規模製造
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
LT3215187T (lt) 2014-11-04 2018-12-27 Janssen Vaccines & Prevention B.V. Terapinės hpv16 vakcinos
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された可溶性融合前rsv fポリペプチド
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
SG10202001501QA (en) 2015-08-20 2020-04-29 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
US10358626B2 (en) * 2016-04-12 2019-07-23 Artemis Biosystems, Inc. Perfusion filtration systems
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用hpvワクチン組み合わせ
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Hpvワクチン
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. Rsv感染に対する防御免疫を誘導するための方法及び組成物
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
CA3077630A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
MX2020004492A (es) 2017-10-31 2020-11-24 Janssen Vaccines & Prevention Bv Adenovirus y usos de los mismos.
BR112020011627A2 (pt) * 2017-12-11 2020-11-17 Amgen Inc. processo de fabricação contínuo para produtos de anticorpos biespecíficos
CN110317832B (zh) * 2018-03-28 2022-07-05 西比曼生物科技(香港)有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技(香港)有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
US20210047626A1 (en) 2018-04-24 2021-02-18 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
BR112022000061A2 (pt) * 2019-07-01 2022-05-24 Ology Bioservices Inc Método para o cultivo de células aderentes em um bioreator multiparalelo
WO2021155323A1 (en) 2020-01-31 2021-08-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
WO2022207839A2 (en) 2021-04-01 2022-10-06 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04241381A (ja) 1991-01-16 1992-08-28 Brother Ind Ltd 電子学習機
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
CA2230655C (en) 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
CA2258158A1 (fr) 1996-07-01 1998-01-08 Francis Blanche Procede de production d'adenovirus recombinants
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスe1−相補性細胞系
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ES2272053T3 (es) 1998-02-17 2007-04-16 Schering Corporation Composiciones que comprenden virus y metodos para concentrar preparaciones de virus.
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
HUP0102209A2 (hu) 1998-04-22 2001-09-28 Genvec, Inc. Eljárás adenovírus hatékony tisztítására
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
WO2000029024A1 (en) 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1141249A1 (fr) 1998-12-31 2001-10-10 Aventis Pharma S.A. Methode de separation de particules virales
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
AU777041B2 (en) 1999-05-17 2004-09-30 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
WO2001066137A1 (en) 2000-03-07 2001-09-13 Merck & Co., Inc. Adenovirus formulations
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
CA2474763A1 (en) 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
PL208588B1 (pl) 2002-04-25 2011-05-31 Crucell Holland Bv Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa
JP4495587B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
ES2357366T3 (es) 2002-05-14 2011-04-25 MERCK SHARP & DOHME CORP. Procedimientos de purificación de adenovirus.
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
SG156535A1 (en) 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
CA2519680A1 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
DK1670925T3 (da) 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
CN1930281A (zh) * 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
CN101001945B (zh) 2004-06-04 2012-02-08 艾克塞勒雷克斯公司 一次性生物反应器系统及方法
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
BRPI0518146A (pt) 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
BRPI0518933A2 (pt) 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
JP2008538894A (ja) 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型26ベクター、核酸およびそれにより製造されたウイルス
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CA2609276A1 (en) 2005-05-23 2006-11-30 De-Chu C. Tang Rapid production of adenovirus-free recombinant adenovirus vectors
WO2007010409A2 (en) 2005-07-22 2007-01-25 Pergo (Europe) Ab Flooring system including a preglue
US20070178115A1 (en) 2005-08-15 2007-08-02 Tang De-Chu C Immunization of avians by administration of non-replicating vectored vaccines
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP1998804B1 (en) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
KR20090094213A (ko) 2006-07-18 2009-09-04 글락소스미스클라인 바이오로지칼즈 에스.에이. 말라리아 백신
BRPI0808553A2 (pt) 2007-03-02 2014-08-19 Glaxosmithkline Biolog Sa Métodos para elevar uma resposta imune contra um patógeno, para estimar a produção de células t cd4+ e/ou cd8+ e/ou anticorpos específicos de patógeno em mamíferos e para estimular uma resposta imune em um mamífero, composição de vacina, uso da mesma, e, kit
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
JP5795164B2 (ja) 2007-11-14 2015-10-14 チャン、チュン−チエ リチウムイオン電池での適用のための空気感受性電極材料を製造するための方法および装置
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
JP5770633B2 (ja) 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
WO2011006823A1 (en) 2009-07-16 2011-01-20 Crucell Holland B.V. Production of polio virus at high titers for vaccine production
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
US20120315696A1 (en) 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors

Also Published As

Publication number Publication date
ES2532015T3 (es) 2015-03-23
CN102203242A (zh) 2011-09-28
EP2350268B1 (en) 2014-12-24
PL2350268T3 (pl) 2015-05-29
NZ593235A (en) 2013-02-22
US20110207202A1 (en) 2011-08-25
AU2009319254A1 (en) 2010-06-03
KR20110093793A (ko) 2011-08-18
DK2350268T3 (en) 2015-03-23
JP2012507270A (ja) 2012-03-29
CA2742474A1 (en) 2010-06-03
CA2742474C (en) 2016-05-31
MX2011004292A (es) 2011-05-31
EP2350268A1 (en) 2011-08-03
AU2009319254B2 (en) 2015-04-30
EA201170638A1 (ru) 2011-12-30
EA019928B1 (ru) 2014-07-30
CN102203242B (zh) 2013-06-12
JP5770633B2 (ja) 2015-08-26
US10041049B2 (en) 2018-08-07
WO2010060719A1 (en) 2010-06-03
HK1160664A1 (en) 2012-08-10
KR101504392B1 (ko) 2015-03-19

Similar Documents

Publication Publication Date Title
BRPI0921651A2 (pt) Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
BRPI0919575A2 (pt) método, e, composição
EP2424814A4 (en) OPTICAL MATERIALS, OPTICAL COMPONENTS AND METHOD
BRPI0914145A2 (pt) métodos para produzir polimerização por radical controlada, e para obter distribuição por radical atva controlada.
BRPI0919199A2 (pt) suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparas as mesmas
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BR112012005424A2 (pt) método para produzir n-propanol, e, microorganismo
BR112012000296A2 (pt) composição e método para produção de um propante cerâmico ultraleve.
BR112012002657A2 (pt) composição polimerizável para material ótico, material ótico e processo para produção de material ótico
BRPI0823277A2 (pt) Composição, e , método
BRPI0921106A2 (pt) biocombustível e processo para preparação de biocombustível
GB0822068D0 (en) Methods for virus design
BRPI0921438A2 (pt) Hospedeiros e processos de fermentação para produção de celulase
EP2767527A4 (en) METHOD FOR MANUFACTURING CERAMIC BEES NICKEL STRUCTURE AND CERAMIC BEES NUT STRUCTURE
BRPI0917714A2 (pt) método para preparar uma microesfera de liberação prolongada, e, microesfera de liberação prolongada
BRPI1014516A2 (pt) Biorreator de estado sólido, estático, e método para usar o mesmo
BRPI0921380A2 (pt) processo para preparar partículas oxidantes, e, partículas oxidantes de tamanho reduzido
BRPI0823238A2 (pt) Composição, e, método
BRPI1006996A2 (pt) composição, método e uso
BRPI0918633A2 (pt) método para calcinar matérias-primas.
EP2767528A4 (en) METHOD FOR PRODUCING A CERAMIC WAVE STRUCTURE AND CERAMIC WAVE STRUCTURE
BR112013030382A2 (pt) célula hospedeira recombinante, composição, e, métodos para produzir n-propanol e propileno
FI20075192A0 (fi) Menetelmät analyysien valmistelemiseksi ja suorittamiseksi

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.